08:43 AM EDT, 06/04/2025 (MT Newswires) -- Natera ( NTRA ) said Wednesday that its Signatera Genome test is now covered by Medicare for multiple cancer types.
The expanded coverage is consistent with previously approved indications for the Signatera test, which include colorectal, breast, lung, bladder, and ovarian cancer, Natera ( NTRA ) said.
The company said the decision was supported by published clinical data.